Metyrapone/oxazepam - Embera

Drug Profile

Metyrapone/oxazepam - Embera

Alternative Names: EMB 001C; EMB-001

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Louisiana State University
  • Developer Embera NeuroTherapeutics
  • Class Antidepressants; Antihormones; Anxiolytics; Benzodiazepinones; Pyridines
  • Mechanism of Action GABA A receptor agonists; Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Cocaine abuse

Highest Development Phases

  • Phase I Smoking withdrawal
  • No development reported Cocaine abuse

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cocaine-abuse in USA (PO)
  • 08 May 2017 Adverse events and pharmacokinetics data from a phase Ib trial in Cocaine abuse released by Embera NeuroTherapeutics
  • 08 May 2017 Embera NeuroTherapeutics plans a phase II trial for Smoking withdrawal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top